Akron Children's Hospital > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

Fesoterodine for Children with Bladder Over activity

Safety and Efficacy of Fesoterodine in Children with Bladder Overactivity

Description:

Fesoterodine is a drug approved in Europe and USA to treat an overactive bladder condition known in adults but due to lack of research it is not yet FDA approved for children. This bladder condition has been associated with damage to the nervous system and is known as Neurogenic detrusor over activity (NDO).

The purpose of this trial is to study the effects of the Fesoterodine medicine provided to children diagnosed with NDO. We will also compare the effects of Fesoterodine with Oxybutynin, a widely approved medicine commonly used to treat NDO in children.

For more information visit: https://clinicaltrials.gov/ct2/show/NCT01557244?term=Fesoterodine&rank=1

Who May Qualify?:

Children between 6-17 years of age diagnosed with neurogenic detrusor overactivity (NDO).

Who Does Not Qualify:

Complete exclusion criteria information.

Study Status:

Closed

Study Sponsor:

Pfizer, Inc.

Full IRB Study Title:

A 24-week Randomized, Open-label, Study To Evaluate The Safety And Efficacy Of Fesoterodine In Subjects Aged 6 To 17 Years With Symptoms Of Detrusor Over activity Associated With A Neurological Condition (Neurogenic Detrusor Over activity)

IRB Study ID:

120613

If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org

Lead Investigator